MedTrace Logo

A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers

NCT01146938 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2012-01-05

No results posted yet for this study

Summary

To compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in hepatic impairment patients and healthy volunteers

Conditions

  • Essential Hypertension
  • Hepatic Impairment

Interventions

DRUG

fimasartan

single administration of fimasartan 120mg

DRUG

fimasartan

single administration of fimasartan 120mg

Sponsors & Collaborators

  • Kyungpook National University Hospital

    collaborator OTHER

  • Yonsei University

    collaborator OTHER

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Minsoo Park, PhD · Yonsei University

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
64 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01146938 on ClinicalTrials.gov